Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-370 Phase III clinical study in infants
jRCT2080223917Phase 3Completed
- Sponsor
- KM Biologics
- Start
- May 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Quentiv in Haemophilus influenzae type b disease (Hib), pertussis, diphtheria and 2 more (2 arms), sponsored by KM Biologics. Primary endpoints: Immunogenicity non-inferiority vs ActHIB + Quattrovac after primary immunization, Immunogenicity after booster dose and 1 more. Started May 2018; status: completed.
02
Drugs
Quentiv
03
Conditions
Haemophilus influenzae type b disease (Hib)pertussisdiphtheriaTetanuspoliomyelitis
Beyond the preview
Go deeper on jRCT2080223917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223917.